Research Article | Open Access
Savita Bisht, Jens Nolting, Jörg Wenzel, Peter Brossart, Georg Feldmann, "EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress", Journal of Oncology, vol. 2019, Article ID 8701824, 13 pages, 2019. https://doi.org/10.1155/2019/8701824
EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress
Therapeutic options for advanced stage cholangiocellular carcinoma (CCC) are very limited as of today and patients carry an exceptionally poor overall prognosis. In recent years, increasing evidence has been accumulated to suggest that malignant cells widely show increased intrinsic ROS levels and exhibit altered redox profiles as compared to normal counterparts, opening up potential avenues for therapeutic intervention. This study provides preclinical experimental evidence of therapeutic activity of the curcumin analog EF24 in cholangiocarcinoma models. In CCC cell lines, EF24 inhibited cell viability and induced apoptosis through excessive ROS generation. Moreover, administration of EF24 led to depletion of total intracellular GSH levels, induced mitochondrial depolarization, and abrogated STAT3 phosphorylation. Of interest, these effects were readily averted by treating the cells with exogenous antioxidants such as N-acetyl cysteine (NAC) or glutathione monoethyl ester (GEE). In vivo, EF24, solubilized using a cyclodextrin formulation, significantly suppressed the growth of tumor xenografts without exhibiting any toxic adverse effects. Immunohistochemical analysis of extracted tumor tissues demonstrated reduced nuclear staining for Ki-67 and downregulation of phospho-STAT3 as well as strong staining for oxidative stress biomarker 8-OHdG. Therefore, the data presented here suggest EF24 as potential therapeutic compound against CCC which might act at least to some extent through ROS-induced oxidative damage, subsequently inducing apoptosis. Further evaluation of this approach should be carried out in future follow-up studies.
Cholangiocellular carcinoma (CCC) is the second most common cancer of the hepatobiliary tract and arises from malignant transformation of cholangiocytes lining intra- and extrahepatic bile ducts [1, 2]. Although cholangiocarcinomas comprise 10-15% of all hepatobiliary neoplasms, their incidence and mortality rates are rising worldwide . Most of the currently available treatment options for advanced CCC such as biliary drainage, systemic therapy with tyrosine kinase inhibitors, conventional chemotherapy, or photodynamic therapy show limited effects on overall survival and quality of life. Thus, novel therapeutic strategies are needed to improve quality of life and outcome for cholangiocarcinoma patients.
In recent years, ROS stress in cancer cells and its potential therapeutic implications have emerged as a promising area of research. Mounting evidences suggest that, due to increased metabolic activity, oncogenic stimulation, and mitochondrial malfunction, cancerous cells produce higher levels of ROS and are thus constantly in a state of increased chronic oxidative stress as compared to noncancerous counterparts [4–8]. Although moderate increase in ROS production promotes carcinogenesis and cancer progression due to their stimulating effects on cell growth and proliferation [9–14], excessive production and accumulation of ROS can cause irreversible cellular damage triggering cell death . Of interest, increased basal oxidative stress in cancerous and transformed cells renders them highly dependent on antioxidant systems to counteract the damaging effects of ROS [16–19], opening up potential avenues for therapeutic intervention by agents that confer further oxidative pressure.
This present study identifies the curcumin analog EF24 as potential therapeutic agent with the potential to target cholangiocellular carcinoma cells by enhancing excessive ROS production while at the same time quenching antioxidative response.
2. Materials and Methods
Curcumin and its analog EF24 were purchased from Sigma-Aldrich (Steinheim, Germany). Stock solutions of each (20 mM) were prepared in DMSO and stored in aliquots at -20°C. The compounds were diluted in culture media prior to each experiment. N-acetyl-L-cysteine (NAC) was also obtained from Sigma-Aldrich and dissolved in double distilled water. Recombinant human IL-6 (RELIATech GmbH), Annexin V/PI kit (BD Biosciences, Schwerte, Germany), Total ROS/Superoxide Detection Kit (Enzo Life Sciences GmbH, Lörrach, Germany), and ApoGSH™ Glutathione Colorimetric Assay Kit (BioVision, Milpitas, CA) were used according to the respective protocol recommended by the manufacturer.
2.2. Cell Culture
Human cholangiocarcinoma cell lines were grown in RPMI media (PAA Laboratories, Pasching, Austria) supplemented with 10% fetal bovine serum, 1x penicillin-streptomycin (PAA Laboratories, Pasching, Austria), and 5 μg/mL of plasmocin (InvivoGen, San Diego, CA). All cell lines were grown in a humidified atmosphere at 37°C in the presence of 5% CO2 and were routinely tested for mycoplasma infection using a PCR-based assay as described elsewhere . Cells were treated with EF24 dissolved in DMSO with final concentrations of DMSO not exceeding 0.1%. DMSO-treated cells were used as mock controls in all the experiments.
SNU478 is a human biliary tract cancer cell line derived from a histologically confirmed Ampulla of Vater carcinoma in a Korean patient; its parent tumor was found to represent a poorly differentiated adenocarcinoma with signet ring cell feature and infiltrated to the pancreas along the interstitial space as a single cell or cell cords . HuCC-T1 is one of the most widely used human cholangiocellular carcinoma cell lines, originally established in vitro from the malignant cells of ascites of a 56-year-old patient and proven to faithfully preserve key genetic alterations and protein expression patterns reminiscent of human biliary tract cancer .
2.3. Cell Viability (MTS) Assays
Cell viability of cholangiocarcinoma cell lines was determined using MTS assays as described previously [23, 24]. Briefly, 5000 cells/well were plated in 96-well plates and were treated with increasing concentrations of 0, 0.1, 0.5, 1.0, and 5.0 μM of free curcumin or equivalent doses of EF24, respectively, for 24, 48, and 72 hours, at which point the assay was terminated, and relative growth inhibition compared to mock-treated cells was measured using CellTiter 96 reagent, as recommended in the manufacturer's protocol. All experiments were set up in triplicates to determine means and standard deviations.
2.4. Clonogenicity Assays
Cells were seeded at a density of 1,000 per well into six well plates and treated with increasing concentrations of EF24 for 24 hours. DMSO was added in control wells. On the following day, media-containing drug was removed and the cells were washed with PBS. Fresh growth medium was then added to the cells. Once colonies became visible, cells were fixed with 70% ethanol and stained with 0.05% (w/v) crystal violet solution (Sigma-Aldrich, Steinheim, Germany).
2.5. Annexin V-FITC/PI Apoptosis Assays
SNU478 and HuCC-T1 cells were treated with 1 μM or 5 μM of EF24 for 24 hours. DMSO was used as mock control. After treatment, cells were harvested, washed in ice-cold PBS, and resuspended in 500 μL of 1x binding buffer containing 5 μl of Annexin-V and 5 μL of PI solution. Cells were incubated at room temperature for 15-20 minutes in the dark and were then immediately analyzed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA).
2.6. Measurement of Intracellular Reactive Oxygen Species (ROS)
Intracellular ROS and superoxide levels were measured using Total ROS/Superoxide Detection Kit (Enzo Life Sciences, Lörrach, Germany). Briefly, cells were cultured and treated with appropriate concentration of EF24 in the absence and presence of NAC. After 8 hours, media was removed and the cells were washed twice with 1x wash buffer. The cells were then trypsinized, centrifuged for 5 min at 400 x g, and further resuspended in 500 μl of ROS/superoxide detection solution. Cells were stained at 37°C for 30 min in the dark and immediately analyzed by flow cytometry.
2.7. Measurement of Total Cellular Glutathione (GSH) Content
Total glutathione (GSH) levels in cell extracts were measured using Total Glutathione Colorimetric Assay Kit (BioVision). Briefly, cells treated with DMSO or EF24 were lysed in ice-cold glutathione buffer and deproteinized using ice-cold 5% (w/v) sulfosalicylic acid (SSA). The lysates were centrifuged at 8000 x g for 10 minutes, and the collected supernatants were used for glutathione assays according to the manufacturer's protocol. The amount of GSH was calculated from a standard curve generated under similar conditions.
2.8. Mitochondrial Membrane Potential Measurement (Δψm)
One million of cells untreated or treated with different concentrations of EF24 were resuspended in 1 mL of RPMI medium and loaded with 250 nM fluorescent probe, tetramethyl rhodamine methyl ester (TMRM). Cells were then incubated for 25 minutes at 37°C in the dark, washed twice with PBS, and resuspended again in FACS buffer prior to data acquisition by flow cytometry.
2.9. Western Blots
SNU478 and HuCC-T1 cells were treated with two different concentrations of EF24 (1 μM or 5 μM) or DMSO for 24 h. Next, cells were lysed using radioimmunoprecipitation assay buffer (RIPA: 1% Igepal CA 630, 0.5% sodium deoxycholate, 0.1% SDS, and 2 mM EDTA) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich, Steinheim, Germany). 50 μg of total protein was separated using 4-12% NuPAGE Bis-Tris Gels (Life Technologies, Darmstadt, Germany) and transferred onto PVDF membranes (Millipore, Billerica, MA, USA). The blots were blocked using either 5% (w/v) BSA or 5% (w/v) milk in TBST for 1 hour and then probed using primary antibodies against BAX, BCL2, phospho-STAT3, STAT3, caspase 3, cleaved caspase 3, PARP, or GAPDH (1:1000, Cell signaling, Danvers, MA). HRP-coupled secondary antibodies directed against rabbit or mouse IgG, respectively (1:2000. Cell Signaling, Danvers, MA), were subsequently used. Detection was performed as previously described . Quantification was done by densitometry using ImageJ analysis software (https://imagej.nih.gov/ij/).
2.10. Xenograft Studies
All animal experiments described were approved by the local authorities. Mice were maintained and handled in accordance with the guidelines of the Federation of European Laboratory Animal Science Associations (FELASA). SNU478 xenografts were generated by injecting 2.5 x 106 cells resuspended in a total volume of 200 μL [PBS/Matrigel (BD Biosciences), 1:1 (v/v), prechilled to 4°C] subcutaneously into the flanks of 6-8-week-old NOD-SCID HPRT mice . After two weeks, subcutaneous tumors were measured using digital calipers (Milomex, Pulloxhill, UK) and tumor volumes V were calculated as V=1/2(ab2), where a is the longest and b is the shortest orthogonal tumor diameter . Mice were then randomized into two cohorts (n=6 animals per cohort) and assigned to either of the following treatment regimens: (i) 2-hydroxypropyl-beta-cyclodextrin as vehicle only or (ii) EF24 solubilized in 10% (w/v) 2-hydroxypropyl-beta-cyclodextrin (AppliChem, Darmstadt, Germany) at a daily dose of 10 mg/kg i.p. Tumor volumes and body weights were measured weekly. After three weeks, tumors were harvested and fixed in 10% buffered formalin solution for further immunohistochemical analysis.
2.11. Statistical Analysis
Two-tailed Student’s t-test and Mann-Whitney U test were performed using GraphPad Prism for Windows version 6. Kruskal-Wallis analyses were done using SPSS for Microsoft Windows. p<0.05 was regarded as statistically significant. Unless indicated otherwise, results are shown as mean ± standard deviation.
3.1. EF24 Inhibits Growth and Clonogenicity of Cholangiocarcinoma Cells
Net cell growth of established cholangiocarcinoma cell lines SNU478 and HuCC-T1 was evaluated in the presence of increasing concentrations of EF24 or its parent compound curcumin, respectively, by means of cell viability (MTS) assays. As shown in Figure 1(a), EF24 potently inhibited net cell growth of both SNU478 or HuCC-T1 cells, respectively, in a dose- and time-dependent manner. Next, the in vitro efficacy of EF24 on clonogenicity of SNU478 and HuCC-T1 cells was determined using single cell suspension replating assays (Figure 1(b)). Here, EF24 drastically reduced the ability of both cell lines to form colonies at concentrations in the range of 100-250 nM (Figure 1(c)). As opposed to this observation, the parent compound curcumin did not cause any tangible growth inhibition at concentrations of up to 5 μM in MTS assays and also did not show any effect on the clonogenic potential of SNU478 or HuCC-T1 cells at concentrations of up to 1 μM (Supplementary Figure 1).
3.2. EF24 Induces Apoptosis in CCC Cells
In order to better understand the mechanism underlying the observed reduction of in vitro net CCC cell growth caused by treatment with EF24, we next evaluated its effect on apoptosis using Annexin binding assays. Flow cytometry analysis of Annexin-V/PI stained SNU478 and HuCC-T1 cells revealed significant induction of apoptosis, including an increase in both early and late apoptotic states, upon treatment with EF24 in a concentration-dependent manner (Figure 2(a)). In line with this finding, after treatment with EF24 (at concentrations of 1 μM or 5 μM, resp.) both SNU478 and HuCC-T1 cells showed increased levels of cleaved PARP and cleaved caspase 3 as biomarkers of apoptosis, as well as reduction in BCL2 (antiapoptotic) and concomitant increase in BAX (proapoptotic) protein levels as determined using Western blot analysis (Figure 2(b)).
3.3. Increase in Oxidative Stress Plays an Essential Role in EF24-Induced Apoptosis and Cell Death
It has previously been shown that many anticancer agents induce ROS-mediated killing of cancer cells by significant accumulation of ROS leading to oxidative damage and cell death . To investigate whether EF24 increases ROS levels in SNU478 and HuCC-T1 cells, we measured total ROS and superoxide levels in EF24-treated cells using flow cytometry. Interestingly, for both cholangiocellular carcinoma cell lines tested, flow cytometry revealed a significant increase in intracellular superoxide free radical () levels upon treatment with EF24 at 5 μM as compared to mock-treated controls; an increase in intracellular total ROS levels was also observed. As expected, prior treatment with the broad-spectrum antioxidant N-acetyl cysteine (NAC; 5 mM) efficiently attenuated generation of ROS and superoxide in these cells (Figure 3(a)). Additionally, the morphology of the cells was also found to be completely protected from the effects of EF24 when coadministered with NAC (data not shown). However, given the fact that the degree of oxidative stress reflects the balance between the rate of ROS production and the activity of the scavenging systems that detoxify them, we next investigated the effect of EF24 treatment on the status of intracellular glutathione (GSH). As shown in Figure 3(b), treatment with EF24 significantly depleted total GSH levels. Moreover, pretreatment with NAC, a well-described precursor of GSH, was sufficient to completely prevent EF24-mediated GSH depletion.
3.4. EF24-Induced Apoptosis Is Rescued by NAC
Next, in order to further dissect whether EF24-mediated cytotoxicity and apoptosis in cholangiocarcinoma cell lines is mediated by excessive ROS accumulation, we performed in vitro cell viability, clonogenicity, and apoptosis assays in the absence or presence of NAC (Figure 4). Of note, addition of NAC rescued growth retardation in HuCC-T1 as well as SNU478 cells conferred by EF24 in a dose- and time-dependent manner (Figure 4(a)). While treatment with EF24 administered at doses of 1 or 5 μM, respectively, led to near-complete abrogation of colony formation of SNU478 or HuCC-T1 cells in replating assays, this phenotype, too, was rescued by coadministration of NAC (Figure 4(b)). Finally, Western blot analyses revealed that in both cell lines NAC-mediated rescue of in vitro clonogenicity and net cell growth were accompanied by resuppression of apoptosis biomarkers, cleaved PARP and cleaved caspase 3 (Figure 4(c)).
Thus, taken together, all of these experiments showed that pretreatment with the antioxidant NAC completely prevented EF24-mediated growth inhibition and induction of apoptosis in CCC cells. Our results therefore strongly indicate that EF24 increases oxidative stress, possibly by generating exorbitant levels of ROS but also by undermining the ability of cells to detoxify these oxidants, with this shift in oxidative species balance eventually causing induction of apoptosis and cancer cell death.
3.5. EF24 Disrupts Mitochondrial Membrane Potential in Cholangiocarcinoma Cells
Dissipation of mitochondrial membrane potential (MMP) is another central mechanism known to be frequently involved in mediating drug-induced apoptosis. Excessive intracellular ROS production has been shown to induce apoptosis by disrupting MMP [28, 29]. Therefore, in order to examine a potential involvement of mitochondria in EF24-induced ROS-mediated apoptosis in CCC cells, we evaluated the induction of mitochondrial membrane damage by EF24. Functional integrity of mitochondrial membranes was assessed by flow cytometry after the cells were labeled with tetramethyl rhodamine methyl ester (TMRM), a dye that accumulates in intact mitochondria and emits red fluorescence. Decrease in fluorescence intensity indicates loss of transmembrane potential . As shown in Figure 5, treatment with EF24 led to depolarization of mitochondria and reduction of membrane potential in a dose-dependent manner, with the maximum drop seen at the highest concentration of EF24 administered (c=5 μM) as indicated by a significant decrease in TMRM fluorescence signal intensity.
3.6. EF24 Inhibits Phosphorylation of STAT3
Constitutive STAT3 activation in cholangiocellular carcinomas has previously been shown to be centrally involved in regulating oncogenic gene transcription, tumor progression, and resistance to apoptosis [31–33]. In order to evaluate potential effects of EF24 on STAT3 activation, both cell lines were treated with increasing concentrations of EF24 or solvent for 2, 6, or 24 hours and subjected to Western blot analysis of phosphorylated STAT3 levels. We found that EF24 inhibited STAT3 phosphorylation at tyrosine residue Tyr705 in a dose- and time-dependent manner without affecting total STAT3 protein expression levels (Figure 6). Furthermore, immunofluorescence studies were performed to examine the intracellular localization of STAT3 in SNU478 cells in response to EF24 treatment. Fluorescence images revealed that EF24 prevented nuclear translocation of STAT3 even in the presence of IL-6, whereas mock-treated cells showed nuclear accumulation of STAT3 to a larger extent after IL-6 stimulation (Figure 6(b)).
3.7. EF24-Induced Glutathione- (GSH-) Depletion Inhibits Phosphorylation of STAT3
In order to dissect the molecular mechanism underlying inhibition of STAT3 phosphorylation by EF24, we hypothesized that increased reactive oxygen species (ROS) levels and rapid drop in intracellular glutathione (GSH) levels might have an important role in this context. Several lines of evidence suggest that STAT3 activation is susceptible to redox regulation where excessive oxidative stress triggers irreversible modification of thiol groups of this protein, finally causing its S-glutathionylation with concomitant inhibition of its phosphorylation . To corroborate whether or not these mechanisms are in fact involved in modulating STAT3 pathway activity in cholangiocarcinoma cells upon administration of EF24, SNU478 and HuCC-T1 cells were pretreated with either 10 mM N-acetyl cysteine (NAC), a precursor to GSH, or a cell permeable glutathione monoethyl ester (GEE; c = 10 mM), which is cleaved to GSH intracellularly, for 2 hours and thereafter with 2.5 μM EF24 for another 6 hours (Figure 6(c)). Western blot analysis revealed that both antioxidants, NAC and GEE, completely reverted inhibition of STAT3 phosphorylation by EF24, hence implying that the protective effects are due to their ability to either increase or sustain the intracellular GSH pool.
3.8. EF24 Inhibits Cholangiocarcinoma Growth In Vivo
Exploiting differential redox states between normal and neoplastic cells has long been suggested as potential therapeutic approach to target various cancer tissues . However, the introduction of ROS-generating compounds as potential novel drug candidates has been hampered by several caveats; namely, it was found to be difficult to prove therapeutic selectivity between normal and malignant cells . Therefore, thorough preclinical evaluation of therapeutic efficacy including tests in suitable in vivo model systems is crucial for each such compound in question.
To assess the therapeutic effect of EF24 on tumor growth in vivo, SNU478 xenografts were generated in 6-8-week-old NOD-SCID HPRT mice and allowed to grow to an average size of 80 mm3, at which point EF24 solubilized in 10% (w/v) cyclodextrin (EF24-CD) was administered daily to (n=6) mice intraperitoneally for three consecutive weeks. Mice in the control arm (n=6) were mock-treated with cyclodextrin. As shown in Figure 7, treatment with EF24 led to considerable growth retardation of established SNU478 xenograft tumors as compared to controls, with significant differences in average tumor volumes (Figures 7(a) and 7(c)) as well as tumor weights (Figure 7(b)) observed after treatment for three weeks. Thorough necropsy and histological examination of major organs performed at the end of treatment did not reveal any apparent signs of toxicity or difference in mean body weights between the respective treatment arms (data not shown). Of interest, in line with the in vitro data reported above and with the observed in vivo growth inhibition, EF24-treated xenografts showed reduced nuclear Ki-67 staining as compared to mock-treated controls using immunohistochemistry, in line with reduced proliferation (Figure 7(d)). Further, the phosphorylation status of STAT3 found in resected tumor sections correlated with the results obtained in the cell lines and showed markedly reduced levels of p-STAT3 in EF24-treated tumor tissues. Of note, strongly increased expression of 8-OHdG, a biomarker for oxidative damage, was found in EF24-treated tumor tissues, thus confirming EF24-mediated increase in oxidative stress in CCC cells in vivo in the xenograft model utilized here.
In this current study, we show that the curcumin analog EF24 inhibits progression of human cholangiocarcinoma using preclinical in vitro and in vivo model systems and that this compound should thus be further evaluated as potential therapeutic agent for this difficult-to-treat malignancy. These data are in line with a previous report by our own group demonstrating in vivo therapeutic efficacy of a liposomal nanoformulation of EF24 in pancreatic cancer xenografts .
Various lines of evidence hint at potential therapeutic efficacy of curcumin and its analog EF24 in a variety of human malignancies [37, 38]. Here we show that EF24 inhibits proliferation, migration, and clonogenicity through induction of apoptosis by increasing oxidative stress in cholangiocarcinoma cells. It has long been suggested that free radicals and increased oxidative stress might contribute to DNA damage and carcinogenesis, and hence antioxidants have been proposed as potential prophylactic agents against neoplasia . However, more recent evidence suggests that this simplistic view does not always seem to be correct and antioxidants have often failed to demonstrate prophylactic properties or have even been found to increase cancer risk, thus indicating more complex underlying regulatory networks modulating oxidative stress in normal as well as in neoplastic cells [40, 41]. It has been noted that oncogenic signals acquired during malignant transformation might both induce ROS generation and hence stimulate cell proliferation through redox-sensitive transcription factors and at the same time promote antioxidant adaptive mechanisms to minimize oxidative damage . In cancer cells, increased overall ROS stress has been found to correlate with tumor aggressiveness and adverse prognosis [42, 43]. One of the mechanisms acquired by cancer cells in order to counteract potential toxic effects conferred by elevated ROS levels appears to be concomitant upregulation of antioxidants , as suggested by the observation of increased peroxiredoxin-3 and thioredoxin peroxidase levels in H-ras transformed cells as compared to nontumorigenic counterparts . Moreover, Ras-transformed cells have been shown to be more vulnerable to glutathione depletion with subsequent ROS accumulation and ROS-induced cell death, and ROS-induction by treatment with beta-phenylethyl isothiocyanate (PEITC) led to selective killing of cancer cells and enhanced survival in murine Ras-transformed ovarian cancer xenografts . Therefore, Trachootham et al. hypothesized that, in order to therapeutically target redox-dysregulation in cancer cells that have adapted to oxidative stress by increasing their antioxidant capacity, for example, by upregulation of GSH or GPX, it might not be sufficient to pharmacologically further increase ROS-generation but that a more promising strategy might be to deploy compounds that instead abrogate these adaptive mechanisms, which would then in turn cause a massive accumulation of ROS due to the high basal ROS output in these cells . Our experimental data presented in this current study indicate that EF24 increases oxidative stress in human CCC cell by both increasing ROS levels and at the same time depleting cells of GSH, thus ultimately leading to induction of apoptosis. Of interest and perhaps more importantly, the notion that alteration of redox status might be crucially involved in mediating EF24-induced growth inhibition and apoptosis is further supported by the observation and these effects could be rescued by pretreatment with the antioxidant NAC. Previous studies reported that EF24 and its parent compound curcumin modulate STAT3 phosphorylation . In line with these reports, we were able to show that treatment with EF24 led to reduced phosphorylation of STAT3 at Y705 in cholangiocarcinoma cells. To the best of our knowledge, it is another novel finding of our study that this dephosphorylation might at least in part also be mediated through redox-dependent mechanisms, since this was also partially rescued by antioxidative agents GEE or NAC. Our rescue experiments with NAC and GEE, respectively, provide a strong rationale to suggest that STAT3 phosphorylation might in fact be caused by increased overall oxidative stress. Nevertheless, it can also not completely rule out the fact that STAT3 might also directly contribute to elevated ROS generation, or it might represent mainly a bystander effect.
Since it has been difficult in the past to prove specificity of ROS-mediated elimination of cancer cells , it is an important finding of this present study that the observed effects were not limited to in vitro model systems which have repeatedly been shown to be prone to artifacts but were also found using murine xenografts as suitable in vivo models. Of note, we were not only able to show that EF24 treatment caused significantly delayed CCC xenograft growth but also, perhaps equally important, did not observe any obvious signs of toxicity conferred by this compound at the administered doses, as opposed to earlier experience with other compounds targeting redox balance in the past [46, 47]. This is particularly promising with regard to potential further development towards future clinical application in humans.
Our data is in line with previous reports by others suggesting that various phytochemicals exhibit anticancer properties by altering ROS levels [48–50]. In a recent report, Subramani et al. identified the terpenoid lactone Nimbolide as potential therapeutic agent against pancreatic cancer and were able to show that its therapeutic efficacy is mediated at least in part by excessive generation of ROS, supporting the hypothesis that modulating redox potential plays an important role in cancer cell homeostasis and might be successfully exploited as potential therapeutic target. As opposed to our data presented here, Nimbolide seems to mainly act by increasing total ROS levels, while EF24 was found to also curb antioxidative response mechanisms.
Classic cytotoxic agents such as paclitaxel, doxorubicin, or cisplatin have been shown to induce intracellular ROS production, and it was suggested that resistance of cancer cells to these drugs might correlate with and be potentially due to increase in adaptive antioxidant capacity . It is therefore tempting to speculate whether combination regimens composed of such cytostatic drugs plus agents such as EF24 studied here that reduce antioxidative response might carry the potential to overcome resistance and enhance therapeutic selectivity against cancer cells. Evaluation and thorough preclinical characterization of such combinatorial regimens are therefore an interesting approach that should be addressed in future studies. Of note, clinical application of EF24 and its parent compound curcumin has long been hampered by poor bioavailability, and a cyclodextrin-based delivery method such as the one employed here is not likely to be a viable option for administration in humans. However, nanoparticle-based drug delivery platforms have recently been described by our own group as well as by others with the potential to overcome this obstacle [23, 36, 52, 53], so that at least from a technical point of view such combination studies can rightfully be envisioned.
Moreover, more recent studies provide strong evidence to suggest that, in KRAS mutant tumor cells such as pancreatic ductal adenocarcinoma therapeutic synergism of targeting the glutathione antioxidant pathway is to be expected upon combination with inhibitors of the EGFR or AKT pathways , and therefore based on our data presented here future combination studies of EF24 with cetuximab of small molecule AKT inhibitors appear to be equally exciting.
Taken together, the experimental data presented here suggest that the curcumin analog EF24 induces oxidative stress and should be further evaluated as potential therapeutic compound against cholangiocarcinoma.
|GEE:||Glutathione monoethyl ester|
|MTS:||[3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt|
|ROS:||Reactive oxygen species|
|TBST:||Tris-buffered saline with Tween 20|
|TMRM:||Tetramethyl rhodamine methyl ester.|
The data used to support the findings of this study are included within the article.
Some of the data discussed in this manuscript have been presented as a poster at the 2018 annual meeting of the German Society of Hematology and Oncology (DGHO) in Vienna, Austria.
Conflicts of Interest
The authors state that there are no conflicts of interest that might impair the impartiality of this scientific work.
This work was supported in part by the European Community's Seventh Framework Program [FP7-2007-2013] under Grant Agreement HEALTH-F2-2011-256986, by European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement no. 671881 (INTEGRATA), by the German Cancer Foundation (Deutsche Krebshilfe) under Grants nos. 109215 and 109929 to Georg Feldmann, and by the University Hospital of Bonn, BONFOR, under Grant no. O-142.0005 to Savita Bisht.
Supplementary material contains revised figure showing comparative analysis of therapeutic efficacy of EF24 with its parent compound curcumin (Supplementary Figure 1). (Supplementary Materials)
- H. Malhi and G. J. Gores, “Cholangiocarcinoma: modern advances in understanding a deadly old disease,” Journal of Hepatology, vol. 45, no. 6, pp. 856–867, 2006.
- S. A. Khan, H. C. Thomas, B. R. Davidson, and S. D. Taylor-Robinson, “Cholangiocarcinoma,” The Lancet, vol. 366, no. 9493, pp. 1303–1314, 2005.
- S. A. Khan, S. D. Taylor-Robinson, M. B. Toledano, A. Beck, P. Elliott, and H. C. Thomas, “Changing international trends in mortality rates for liver, biliary and pancreatic tumours,” Journal of Hepatology, vol. 37, no. 6, pp. 806–813, 2002.
- T. P. Szatrowski and C. F. Nathan, “Production of large amounts of hydrogen peroxide by human tumor cells,” Cancer Research, vol. 51, no. 3, pp. 794–798, 1991.
- S. Kawanishi, Y. Hiraku, S. Pinlaor, and N. Ma, “Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis,” Biological Chemistry, vol. 387, no. 4, pp. 365–372, 2006.
- S. Toyokuni, K. Okamoto, J. Yodoi, and H. Hiai, “Persistent oxidative stress in cancer,” FEBS Letters, vol. 358, no. 1, pp. 1–3, 1995.
- D. Kang and N. Hamasaki, “Mitochondrial oxidative stress and mitochondrial DNA,” Clinical Chemistry and Laboratory Medicine, vol. 41, no. 10, pp. 1281–1288, 2003.
- L. Behrend, G. Henderson, and R. Zwacka, “Reactive oxygen species in oncogenic transformation,” Biochemical Society Transactions, vol. 31, no. 6, pp. 1441–1444, 2003.
- Y. Hu, D. G. Rosen, Y. Zhou et al., “Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress,” The Journal of Biological Chemistry, vol. 280, no. 47, pp. 39485–39492, 2005.
- H. Pelicano, L. Feng, Y. Zhou et al., “Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism,” The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37832–37839, 2003.
- J. A. Petros, A. K. Baumann, E. Ruiz-Pesini et al., “MtDNA mutations increase tumorigenicity in prostate cancer,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 102, no. 3, pp. 719–724, 2005.
- Y.-A. Suh, R. S. Arnold, B. Lassegue et al., “Cell transformation by the superoxide-generating oxidase Mox1,” Nature, vol. 401, no. 6748, pp. 79–82, 1999.
- J. Boonstra and J. A. Post, “Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells,” Gene, vol. 337, pp. 1–13, 2004.
- F. Q. Schafer and G. R. Buettner, “Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple,” Free Radical Biology & Medicine, vol. 30, no. 11, pp. 1191–1212, 2001.
- G. Perry, A. K. Raina, A. Nunomura, T. Wataya, L. M. Sayre, and M. A. Smith, “How important is oxidative damage? Lessons from Alzheimer's disease,” Free Radical Biology & Medicine, vol. 28, no. 5, pp. 831–834, 2000.
- D. Trachootham, Y. Zhou, H. Zhang et al., “Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate,” Cancer Cell, vol. 10, no. 3, pp. 241–252, 2006.
- D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009.
- D. Trachootham, W. Lu, M. A. Ogasawara, N. R.-D. Valle, and P. Huang, “Redox regulation of cell survival,” Antioxidants & Redox Signaling, vol. 10, no. 8, pp. 1343–1374, 2008.
- E. O. Hileman, J. Liu, M. Albitar, M. J. Keating, and P. Huang, “Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 3, pp. 209–219, 2004.
- F. J. M. Van Kuppeveld, J. T. M. Van der Logt, A. F. Angulo et al., “Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification,” Applied and Environmental Microbiology, vol. 58, no. 8, pp. 2606–2615, 1992.
- J.-L. Ku, K.-A. Yoon, I.-J. Kim et al., “Establishment and characterisation of six human biliary tract cancer cell lines,” British Journal of Cancer, vol. 87, no. 2, pp. 187–193, 2002.
- M. Miyagiwa, T. Ichida, T. Tokiwa, J. Sato, and H. Sasaki, “A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium,” In Vitro Cellular & Developmental Biology, vol. 25, no. 6, pp. 503–510, 1989.
- S. Bisht, G. Feldmann, S. Soni, R. Ravi, C. Karikar, and A. Maitra, “Polymeric nanoparticle-encapsulated curcumin 'nanocurcumin': a novel strategy for human cancer therapy,” Journal of Nanobiotechnology, vol. 5, pp. 3, 2007.
- G. Feldmann, S. Dhara, V. Fendrich et al., “Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers,” Cancer Research, vol. 67, no. 5, pp. 2187–2196, 2007.
- C. Haan and I. Behrmann, “A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background,” Journal of Immunological Methods, vol. 318, no. 1-2, pp. 11–19, 2007.
- H. Kamiyama, S. Rauenzahn, J. S. Shim et al., “Personalized chemotherapy profiling using cancer cell lines from selectable mice,” Clinical Cancer Research, vol. 19, no. 5, pp. 1139–1146, 2013.
- G. Feldmann, A. Mishra, S. Bisht et al., “Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models,” Cancer Biology & Therapy, vol. 12, no. 7, pp. 598–609, 2011.
- X. Ling, Y. Zhou, S.-W. Li, B. Yan, and L. Wen, “Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells,” International Journal of Biological Sciences, vol. 6, no. 7, pp. 773–783, 2010.
- Y.-B. Ji Yu-Bin, Z.-Y. Qu, and X. Zou, “Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway,” Experimental and Toxicologic Pathology, vol. 63, no. 1-2, pp. 69–78, 2011.
- F. X. Sureda, E. Escubedo, C. Gabriel, J. Comas, J. Camarasa, and A. Camins, “Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry,” Cytometry, vol. 28, no. 1, pp. 74–80, 1997.
- H. Isomoto, S. Kobayashi, N. W. Werneburg et al., “Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells,” Hepatology, vol. 42, no. 6, pp. 1329–1338, 2005.
- H. Isomoto, J. L. Mott, S. Kobayashi et al., “Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing,” Gastroenterology, vol. 132, no. 1, pp. 384–396, 2007.
- D. Sia, V. Tovar, A. Moeini, and J. M. Llovet, “Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies,” Oncogene, vol. 32, no. 41, pp. 4861–4870, 2013.
- Y. Xie, S. Kole, P. Precht, M. J. Pazin, and M. Bernier, “S-Glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling,” Endocrinology, vol. 150, no. 3, pp. 1122–1131, 2009.
- Q. Kong, J. A. Beel, and K. O. Lillehei, “A threshold concept for cancer therapy,” Medical Hypotheses, vol. 55, no. 1, pp. 29–35, 2000.
- S. Bisht, M. Schlesinger, A. Rupp et al., “A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies,” Journal of Nanobiotechnology, vol. 14, no. 1, pp. 57, 2016.
- C. A. Mosley, D. C. Liotta, and J. P. Snyder, “Highly active anticancer curcumin analogues,” Advances in Experimental Medicine and Biology, vol. 595, pp. 77–103, 2007.
- P. R. Dandawate, D. Subramaniam, R. A. Jensen, and S. Anant, “Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy,” Seminars in Cancer Biology, vol. 40-41, pp. 192–208, 2016.
- N. Khansari, Y. Shakiba, and M. Mahmoudi, “Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer,” Recent Patents on Inflammation & Allergy Drug Discovery, vol. 3, no. 1, pp. 73–80, 2009.
- V. I. Sayin, M. X. Ibrahim, E. Larsson, J. A. Nilsson, P. Lindahl, and M. O. Bergo, “Antioxidants accelerate lung cancer progression in mice,” Science Translational Medicine, vol. 6, no. 221, Article ID 221ra15, 2014.
- I. I. Chio, S. M. Jafarnejad, M. Ponz-Sarvise et al., “Abstract PR03: NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer,” Cell, vol. 166, no. 4, pp. 963–976, 2016.
- B. P. Patel, U. M. Rawal, T. K. Dave et al., “Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma,” Integrative Cancer Therapies, vol. 6, no. 4, pp. 365–372, 2007.
- B. Kumar, S. Koul, L. Khandrika, R. B. Meacham, and H. K. Koul, “Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype,” Cancer Research, vol. 68, no. 6, pp. 1777–1785, 2008.
- T. W. Young, F. C. Mei, G. Yang, J. A. Thompson-Lanza, J. Liu, and X. Cheng, “Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry,” Cancer Research, vol. 64, no. 13, pp. 4577–4584, 2004.
- J. Deng, F. Grande, and N. Neamati, “Small molecule inhibitors of Stat3 signaling pathway,” Current Cancer Drug Targets, vol. 7, no. 1, pp. 91–107, 2007.
- R. S. Tuma, “Reactive oxygen species may have antitumor activity in metastatic melanoma,” JNCI: Journal of the National Cancer Institute, vol. 100, no. 1, pp. 11-12, 2008.
- J. R. Kirshner, S. He, V. Balasubramanyam et al., “Elesclomol induces cancer cell apoptosis through oxidative stress,” Molecular Cancer Therapeutics, vol. 7, no. 8, pp. 2319–2327, 2008.
- R. Subramani, E. Gonzalez, A. Arumugam et al., “Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition,” Scientific Reports, vol. 6, p. 19819, 2016.
- P. Seshadri, A. Rajaram, and R. Rajaram, “Plumbagin and juglone induce caspase-3-dependent apoptosis involving the mitochondria through ROS generation in human peripheral blood lymphocytes,” Free Radical Biology & Medicine, vol. 51, no. 11, pp. 2090–2107, 2011.
- H. J. Kim, C. L. Jung, Y. S. Jeong, and J.-S. Kim, “Soybean-derived glyceollins induce apoptosis through ROS generation,” Food & Function, vol. 5, no. 4, pp. 688–695, 2014.
- B. Ramanathan, K.-Y. Jan, C.-H. Chen, T.-C. Hour, H.-J. Yu, and Y.-S. Pu, “Resistance to paclitaxel is proportional to cellular total antioxidant capacity,” Cancer Research, vol. 65, no. 18, pp. 8455–8460, 2005.
- S. Bisht, M. Mizuma, G. Feldmann et al., “Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer,” Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2255–2264, 2010.
- S. Prasad, A. K. Tyagi, and B. B. Aggarwal, “Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice,” Cancer Research and Treatment, vol. 46, no. 1, pp. 2–18, 2014.
Copyright © 2019 Savita Bisht et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.